JP2019532997A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532997A5
JP2019532997A5 JP2019523665A JP2019523665A JP2019532997A5 JP 2019532997 A5 JP2019532997 A5 JP 2019532997A5 JP 2019523665 A JP2019523665 A JP 2019523665A JP 2019523665 A JP2019523665 A JP 2019523665A JP 2019532997 A5 JP2019532997 A5 JP 2019532997A5
Authority
JP
Japan
Prior art keywords
cells
inhibitor
subject
administration
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019523665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532997A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/060060 external-priority patent/WO2018085731A2/en
Publication of JP2019532997A publication Critical patent/JP2019532997A/ja
Publication of JP2019532997A5 publication Critical patent/JP2019532997A5/ja
Priority to JP2023103197A priority Critical patent/JP2023120386A/ja
Withdrawn legal-status Critical Current

Links

JP2019523665A 2016-11-03 2017-11-03 T細胞療法とbtk阻害剤との併用療法 Withdrawn JP2019532997A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023103197A JP2023120386A (ja) 2016-11-03 2023-06-23 T細胞療法とbtk阻害剤との併用療法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662417312P 2016-11-03 2016-11-03
US62/417,312 2016-11-03
US201662429735P 2016-12-03 2016-12-03
US62/429,735 2016-12-03
US201762574706P 2017-10-19 2017-10-19
US62/574,706 2017-10-19
PCT/US2017/060060 WO2018085731A2 (en) 2016-11-03 2017-11-03 Combination therapy of a t cell therapy and a btk inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023103197A Division JP2023120386A (ja) 2016-11-03 2023-06-23 T細胞療法とbtk阻害剤との併用療法

Publications (2)

Publication Number Publication Date
JP2019532997A JP2019532997A (ja) 2019-11-14
JP2019532997A5 true JP2019532997A5 (enExample) 2020-12-17

Family

ID=60515805

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019523665A Withdrawn JP2019532997A (ja) 2016-11-03 2017-11-03 T細胞療法とbtk阻害剤との併用療法
JP2023103197A Pending JP2023120386A (ja) 2016-11-03 2023-06-23 T細胞療法とbtk阻害剤との併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023103197A Pending JP2023120386A (ja) 2016-11-03 2023-06-23 T細胞療法とbtk阻害剤との併用療法

Country Status (9)

Country Link
US (1) US20190298772A1 (enExample)
EP (1) EP3534938A2 (enExample)
JP (2) JP2019532997A (enExample)
CN (1) CN110139669A (enExample)
AU (1) AU2017355544A1 (enExample)
CA (1) CA3042049A1 (enExample)
MA (1) MA46783A (enExample)
MX (2) MX2019005029A (enExample)
WO (1) WO2018085731A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46995A (fr) 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase
KR20240139092A (ko) * 2017-05-01 2024-09-20 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법 및 면역조절 화합물의 조합
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
MX2020004572A (es) 2017-11-01 2020-10-07 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el antigeno de maduracion de celulas b y polinucleotidos que codifican los mismos.
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
WO2020114518A1 (zh) * 2018-12-07 2020-06-11 科济生物医药(上海)有限公司 肿瘤联合免疫治疗
US12240913B2 (en) * 2019-07-26 2025-03-04 Abl Bio Inc. Anti-HER2/anti-4-1BB bispecific antibody and use thereof
CN115087868A (zh) 2019-11-05 2022-09-20 朱诺治疗学股份有限公司 确定治疗性t细胞组合物的属性的方法
CN115485370A (zh) * 2020-03-20 2022-12-16 美国卫生和人力服务部 通过单细胞分析从肿瘤分离t细胞和t细胞受体以用于免疫疗法的方法
WO2021231657A1 (en) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
WO2023278424A1 (en) * 2021-06-28 2023-01-05 The Regents Of The University Of California Methods for treating and ameliorating t cell related diseases
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
WO2025137059A1 (en) * 2023-12-18 2025-06-26 Corvus Pharmaceuticals, Inc. Use of itk inhibitors and car t-cell therapy
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
ES2067018T3 (es) 1988-12-28 1995-03-16 Stefan Miltenyi Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
JP2001519143A (ja) 1997-10-02 2001-10-23 スノル・モレキュラー・コーポレーション 可溶性の一本鎖t細胞レセプタータンパク質
BR9910253A (pt) 1998-05-19 2002-09-17 Avidex Ltd Receptor de célula t solúvel
WO2000014257A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
CA2410510A1 (en) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
AU3113902A (en) 2000-12-21 2002-07-01 Bristol Myers Squibb Co Thiazolyl inhibitors of tec family tyrosine kinases
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
MXPA04001974A (es) 2001-08-31 2004-07-16 Avidex Ltd Receptor de celula t soluble.
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
SE0202461D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0202462D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
SE0202429D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
CA2538032C (en) 2003-09-08 2011-01-11 Aventis Pharmaceuticals Inc. Thienopyrazoles
WO2005070420A1 (en) 2004-01-14 2005-08-04 Boehringer Ingelheim Pharmaceuticals, Inc. 1h-benzimidazol-2-yl-benzamide derivatives and related compounds as itk inhibitors (interleukin-2-inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
WO2005079791A1 (en) 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
JP5563194B2 (ja) 2004-06-29 2014-07-30 イムノコア リミテッド 改変t細胞レセプターを発現する細胞
AU2005316540A1 (en) 2004-12-16 2006-06-22 Vertex Pharmaceuticals Incorporated Pyrid-2-ones useful as inhibitors of Tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases
WO2007016977A1 (de) 2005-08-05 2007-02-15 Delica Ag Vorrichtung zum extrahieren eines in einer kapsel enthaltenen extraktionsgutes mit einem flüssigen extraktionsmittel
ATE548363T1 (de) 2005-08-29 2012-03-15 Vertex Pharma 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
WO2007058832A2 (en) 2005-11-12 2007-05-24 Boehringer Ingelheim International Gmbh Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
WO2007076228A2 (en) 2005-12-20 2007-07-05 Boehringer Ingelheim International Gmbh 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders
AU2007254179B2 (en) 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
ES2549862T3 (es) 2006-08-30 2015-11-02 Cellzome Limited Derivados de triazol como inhibidores de quinasa
EP1900727A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
PL2856876T3 (pl) 2007-03-30 2018-06-29 Memorial Sloan-Kettering Cancer Center Konstytutywna ekspresja ligandów kostymulujących na limfocytach T poddanych transferowi adoptywnemu
US7982036B2 (en) 2007-10-19 2011-07-19 Avila Therapeutics, Inc. 4,6-disubstitued pyrimidines useful as kinase inhibitors
ES2640216T3 (es) 2007-12-07 2017-11-02 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8822647B2 (en) 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
WO2011017219A1 (en) 2009-08-03 2011-02-10 The Regents Of The University Of California Imidazoquinoxalinones and anti-tumor treatment
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
ES2717629T3 (es) 2009-11-03 2019-06-24 Hope City Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
US20130078250A1 (en) 2011-08-23 2013-03-28 Oliver Ast Bispecific t cell activating antigen binding molecules
US10208086B2 (en) 2011-11-11 2019-02-19 Fred Hutchinson Cancer Research Center Cyclin A1-targeted T-cell immunotherapy for cancer
EP3594245A1 (en) 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
CN107557334B (zh) 2012-05-03 2021-06-25 弗雷德哈钦森癌症研究中心 增强亲和力的t细胞受体及其制备方法
WO2013184572A1 (en) 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
PL3824905T3 (pl) 2012-08-20 2025-05-05 Fred Hutchinson Cancer Center Sposób i kompozycje do immunoterapii komórkowej
SG11201502598SA (en) 2012-10-02 2015-05-28 Sloan Kettering Inst Cancer Compositions and methods for immunotherapy
EP2914263A4 (en) 2012-11-02 2016-04-27 Pharmacyclics Inc ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR
US9649313B2 (en) 2012-11-26 2017-05-16 The University Of North Carolina At Chapel Hill Use of ITK inhibitors for the treatment of cancer
US9260426B2 (en) 2012-12-14 2016-02-16 Arrien Pharmaceuticals Llc Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors
JP5372297B1 (ja) 2012-12-20 2013-12-18 三菱電機株式会社 車載装置及びプログラム
WO2014105958A2 (en) 2012-12-26 2014-07-03 Medivation Technologies, Inc. Fused pyrimidine compounds and use thereof
CN105377261B (zh) 2013-03-15 2017-12-15 南特生物科学公司 取代的吲哚‑5‑酚衍生物和它们的治疗应用
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗-cd19嵌合抗原受體治療癌症
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
AU2014368892B2 (en) 2013-12-20 2019-06-13 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
IL322264A (en) * 2014-04-07 2025-09-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
MX2018014911A (es) * 2016-06-06 2019-08-12 Juno Therapeutics Inc Metodos para el tratamiento de afecciones malignas de celulas t usando terapia de celulas adoptivas.
MA46995A (fr) * 2016-12-03 2019-10-09 Acerta Pharma Bv Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase

Similar Documents

Publication Publication Date Title
TWI786044B (zh) 藉由投予pd-1抑制劑治療皮膚癌之方法
AU2017302668B2 (en) Combination therapies of chimeric antigen receptors and PD-1 inhibitors
JP2022031638A (ja) 放射線療法と併用されるpd-1およびpd-l1に対する拮抗薬を用いたがんの治療法
JP2020518591A5 (enExample)
JP2022184862A (ja) 腫瘍微小環境内の機能不全抗原特異的cd8+t細胞
JP2020511462A5 (enExample)
KR20190120792A (ko) 폐암의 치료를 위한 항-pd-1 항체
KR20230148387A (ko) T 세포 요법을 위한 진단 방법
KR20230147769A (ko) T 세포 요법을 위해 환자를 컨디셔닝하는 방법
JP2022537700A5 (enExample)
CN108602889A (zh) 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
CN110248678A (zh) 调节car-t细胞的方法
JP2022513689A5 (enExample)
JP2024519335A (ja) がん免疫療法のための投薬レジメン
Nader et al. Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature
WO2024006925A2 (en) Dosing regimens for cd19-directed cancer immunotherapy
Zhuang et al. Efficacy and immune mechanisms of cetuximab for the treatment of metastatic colorectal cancer
JP2025538424A (ja) 併用療法の投与レジメン
EP4735011A1 (en) Dosing regimens for treatment of cancer
Sibéril Tight Interplay Between Therapeutic Monoclonal
Kato Therapeutic Monoclonal Antibodies for Cancer: The Past, Present, and Future
CN121038798A (zh) Cd4+细胞毒性t细胞及其使用方法
RU2019144333A (ru) Изделия и способы для лечения с использованием адоптивной клеточной терапии
Spear Endogenous Leukocyte Activation by Chimeric Antigen Receptor T cell Immunotherapy